Studies performed in lung cancer models have resulted in interesting novel observations, such as NADPH oxidase NOX1-coordinated inhibition of p53 acetylation at Lys382 that affects p53 proapoptotic function; increased NOX2 expression in NSCLC patients, which correlates with decreased survival (293); and a novel role for the NADPH oxidase NOX3 in the regulation of redox balance in NSCLC causing a selective degradation of mutant EGFR (204). Here, FMO5 is linked to non-small cell lung carcinoma.